OpenAI 收购 Orchestra Bio，用 AI 智能体协调药物研发流程
OpenAI 和 Anthropic 都开始买生物医药团队了，这次收的 Orchestra 专管药物项目里的跨部门协调，跟 Rosalind 的科研推理正好互补。
OpenAI 收购了 Orchestra Bio，这家公司的 AI 智能体负责追踪药物项目的跨部门协调工作。此前 OpenAI 已有 Rosalind 产品线：GPT-Rosalind 负责生物与化学推理，Rosalind Workbench 把模型接入实验室工具与数据。Orchestra 补的是另一块短板——当某批生产失败时，其智能体会梳理哪些试验受影响并给出应对方案。Anthropic 曾在 4 月以约 4 亿美元股票收购 Coefficient Bio，两大实验室都在收购专业生物医药团队。新药从靶点到美国批准平均仍需 10-15 年。
OpenAI bought Orchestra Bio, whose AI agents track drug programs.
Until now, Rosalind covered the science: GPT-Rosalind reasons through biology and chemistry, while Rosalind Workbench links models to lab tools and data.
Orchestra targets a different bottleneck, the coordination work that spreads a drug program across departments, contractors and disconnected software.
Its agents monitor studies and timelines, so when a manufacturing batch fails, they map which trials slip and compare responses for program leaders to choose.
Anthropic paid roughly $400M in stock for Coefficient Bio in April, so both labs are now buying specialist biology teams.
Development still averages 10 to 15 years from target to US approval, a clock largely set by trial biology and regulators.
